BioNTech SE reported €2.87B of revenue over the trailing twelve months, +4.3% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €2.87B (to FY2025). Net income: −€1.14B, trailing twelve months to FY2025. Free cash flow: €281M, trailing twelve months to FY2025. Operating margin: −49%, trailing twelve months to FY2025.

BNTXBioNTech SE

Healthcare

$96.95+0.76% 1Y

$96.95

$83.8952 weeks$119.34

BNTX as reported

BioNTech SE reported €2.87B of revenue over the trailing twelve months, +4.3% on the year before. 10 reported series are charted on this page, each one as filed.

€2.87B

Revenue, trailing twelve months · to FY2025 · +4.3% against the twelve months before

Net income: −€1.14B
Net income · +71% year on year · trailing twelve months to FY2025
Free cash flow: €281M
Free cash flow · −456% year on year · trailing twelve months to FY2025
Operating margin: −49%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for BNTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€2.87B	+4.3%	FY2025
Net income	−€1.14B	+71%	FY2025
EPS	−€4.70	+70%	FY2025
Gross margin	78%	n/a	FY2025
Operating margin	−49%	n/a	FY2025
Net margin	−40%	n/a	FY2025
ROE	−5.9%	n/a	FY2025
ROA	−5.2%	n/a	FY2025
ROIC	119%	n/a	FY2021
Free cash flow	€281M	−456%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.